organization · Reporting owner
Polaris Partners X, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Camp4 Therapeutics Corp
Report date September 11, 2025 · Filed September 11, 2025
Jointly reported with Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners GP X, L.L.C., SCHULMAN AMY W, Chee Brian
Section 16 reporting ended · disclosed 2025-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,825,500 |
Reported balance
After 2025-09-11 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2025-09-11 · Purchase · Acquired 1,221,721 · Balance 2,825,500 F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F2: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 197,661 |
Reported balance
After 2025-09-11 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-09-11 · Purchase · Acquired 85,468 · Balance 197,661 F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F3: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 909,090 |
Reported balance
Holding disclosure · report date 2025-09-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 909,090 F4: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share.
F2: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F4: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2025 Filed Sep 11, 2025 20:59 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 85,468 | $1.53 | $130,766.04 |
DisclosureSEC source: 0001193125-25-201392 · ownership.xml · nonDerivative · entry 2 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 197,661 F1 · kind: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F3 · ownership.nature: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 11, 2025 Filed Sep 11, 2025 20:59 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 1,221,721 | $1.53 | $1,869,233.13 |
DisclosureSEC source: 0001193125-25-201392 · ownership.xml · nonDerivative · entry 1 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,825,500 F1 · kind: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F2 · ownership.nature: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries B Preferred Stock · Derivative | 277,536 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 9 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 24,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries B Preferred Stock · Derivative | 3,967,234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 8 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 353,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries A Prime Preferred Stock · Derivative | 980,829 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 7 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 87,448 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries A Prime Preferred Stock · Derivative | 14,020,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 6 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,250,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 909,090 | $11.00 | $9,999,990.00 |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 5 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 909,090 F5 · ownership.nature: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 24,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 4 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 112,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 353,718 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 3 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,603,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 87,448 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 2 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 87,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 1,250,061 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 1 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,250,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries B Preferred Stock · Derivative | 277,536 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 9 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 24,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries B Preferred Stock · Derivative | 3,967,234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 8 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 353,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries A Prime Preferred Stock · Derivative | 980,829 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 7 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 87,448 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries A Prime Preferred Stock · Derivative | 14,020,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 6 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,250,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 909,090 | $11.00 | $9,999,990.00 |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 5 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 909,090 F5 · ownership.nature: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 24,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 4 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 112,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 353,718 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 3 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,603,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 87,448 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 2 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 87,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 1,250,061 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 1 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,250,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.